Cancer Screening in Raipur

Cancer screening is the testing of people who have no symptoms of cancer to identify abnormalities or early-stage disease before it produces clinical signs. The fundamental premise is simple: most cancers are far more treatable and far more often curable when found at an early stage than when detected only after a patient has developed symptoms. A cervical cancer identified as CIN3 on a Pap smear is treated with a minor outpatient procedure. The same lesion, if unscreened and allowed to progress to invasive cancer with nodal spread, requires chemoradiation and carries a substantially different prognosis.

Screening tests are not diagnostic; they identify people who need further investigation. Many positive screening results are ultimately benign. An abnormal result is an instruction to investigate further.

Why Choose Ramkrishna CARE Hospitals for Cancer Screening Tests in Raipur?

Ramkrishna CARE Hospitals offers comprehensive screening services using advanced technology and expert clinical evaluation:

• Complete multi-cancer screening under one roof: Blood tumour markers, clinical examination, imaging (ultrasound, mammography, and CT), endoscopy (colonoscopy and upper GI endoscopy), Pap smears with liquid-based cytology, and HPV co-testing are all available within the same programme, coordinated by oncology specialists.
• PET CT for high-risk screening: For individuals with a strong family history, hereditary cancer syndromes or prior cancer requiring recurrence surveillance, whole-body metabolic imaging identifies early active lesions. The uMI 550's 2.76 mm resolution and time-of-flight imaging detect lesions as small as 3.5 mm.
• Oncology specialist review: Results are reviewed by oncologists. Borderline or abnormal findings are investigated clinically, and patients are connected immediately to the appropriate specialist.
• Integrated diagnostic plan: When screening identifies an abnormality, the full investigative infrastructure, including CT, MRI, PET CT, endoscopy, biopsy and tumour board review, is available within the same institution.
• Personalised screening plans: Age, sex, family history, prior cancer, lifestyle risk factors and comorbidities all influence which tests are appropriate and how frequently. Our oncology team provides individualised recommendations rather than generic packages.
• Accessible from across Chhattisgarh: Patients from Bilaspur, Durg, Rajnandgaon, Bastar and across Central India attend our programme because comprehensive, oncologist-led cancer screening of this depth is not available at every hospital in the region.

Why Is Cancer Screening Important?

Colorectal cancer detected at stage I has a huge five-year survival rate, which at stage IV falls significantly. Cervical cancer as a precancerous lesion is cured with a minor procedure; advanced cervical cancer requires multimodal treatment with significantly lower cure rates.

In India, most cancers are diagnosed at stage III or IV because screening is not embedded as routine behaviour and symptoms are normalised or attributed to other causes until investigation is too long delayed. Cancer screening inverts this: finding disease in people who feel well, at a stage when clinical options are most favourable.

Types of Cancer Screening Tests

Commonly available screening tests are:

• Pap smear & HPV co-testing: Cervical cells are examined for abnormal changes (CIN) that may progress to cervical cancer; HPV co-testing identifies high-risk strains. Together the most effective cervical cancer prevention strategy is available.
• Mammography: Low-dose X-ray imaging identifying masses, microcalcifications and distortions. Annual or biennial screening from age 40 to 50 reduces breast cancer complications.
• Colonoscopy: It is the gold standard colorectal screening that is both diagnostic and therapeutic. Polyps that would progress to cancer are removed in the same session. Recommended from age 45 for average risk and earlier with family history
• FOBT and FIT: Non-invasive stool tests detecting microscopic blood that is a potential indicator of colorectal cancer or polyps. Positive results require colonoscopy. Annual alternative for individuals declining routine colonoscopy
• PSA blood test: Elevated PSA may indicate prostate cancer, BPH or prostatitis
• Low-dose CT (LDCT) for lung cancer: Recommended for current or former heavy smokers aged 50 to 80 with 20+ pack-years. Detects early nodules before they appear on plain X-ray, reducing lung cancer mortality in high-risk individuals
• Serum tumour markers: Detect AFP (liver cancer surveillance in cirrhosis), CA-125 (ovarian cancer in symptomatic women), CEA (colorectal monitoring) and CA19-9 (pancreatic monitoring).
• Liver cancer surveillance: Six-monthly abdominal ultrasound with AFP for all patients with liver cirrhosis, detecting hepatocellular carcinoma at a resectable or transplantable stage
• PET-CT: For high-risk individuals and cancer survivors, a whole-body metabolic and anatomical assessment in a single examination to identify early lesions that organ-specific screening may miss, including for recurrence surveillance and hereditary cancer syndromes.

Cancer Screening Tests for Men

They are:

• Prostate cancer: PSA and digital rectal examination after discussion with doctor from age 50 for average risk and from age 40 to 45 for men with first-degree relatives diagnosed with prostate cancer before age 65.
• Colorectal cancer: Colonoscopy from age 45 (earlier with family history)
• Lung cancer: Annual LDCT for current or former heavy smokers aged 50 to 80 with 20+ pack-years
• Oral cancer: Annual oral mucosal examination; suspicious lesions referred for specialist evaluation without delay
• Liver cancer surveillance: Six-monthly ultrasound plus AFP for men with cirrhosis from any cause.

Cancer Screening Tests for Women

• Cervical cancer: Pap smear every three years from age 21. HPV co-test every five years from age 30. HPV vaccination does not replace screening, as the vaccine does not protect against all high-risk strains.
• Breast cancer: Clinical breast examination annually. Mammography from age 40 to 50 based on individual risk. High-risk women (BRCA1/2, strong family history & prior chest radiation) may begin earlier and supplement with annual breast MRIs.
• Ovarian cancer: No reliable population screening exists for average-risk women. BRCA1/2 and Lynch syndrome carriers receive specialist surveillance. CA-125 and transvaginal ultrasound are used in symptomatic or high-risk patients.
• Thyroid cancer: Clinical neck examination in symptomatic patients or those with known risk factors. Thyroid ultrasound for nodules meeting examination or imaging criteria

How Is Cancer Screening Performed?

Cancer screening follows a structured process:

• Blood tests: Serum tumour markers via standard venepuncture; results available typically within 24 to 48 hours.
• Pap smear: A brief speculum examination with cervical cell sampling; takes a few minutes with mild discomfort.
• Mammography: Brief breast compression for low-dose X-ray imaging; approximately takes 15 to 20 minutes.
• Colonoscopy: Bowel preparation the day before; procedure under sedation examining the entire colon; procedure takes 30 to 60 minutes, followed by one to two hours' recovery.
• LDCT for lung: Five to ten minutes in the scanner, no contrast, no preparation required.
• Abdominal ultrasound: 20 to 30 minutes, non-invasive, four to six hours of fasting beforehand.
• PET CT: 15 to 30 minutes of scanning with a 60-minute rest after tracer injection. Four to six hours of fasting is required.

When Should You Consult a Doctor?

Individual circumstances may need earlier or more frequent screening than population guidelines suggest. Consult a doctor immediately if you have:

• A first-degree relative diagnosed with cancer before age 50, particularly colorectal, breast, ovarian or prostate cancer
• A known hereditary cancer syndrome like BRCA1/2, Lynch syndrome, familial adenomatous polyposis, or Li-Fraumeni syndrome
• A personal history of cancer – survivorship screening and surveillance are distinct from primary screening.
• Long-standing tobacco or areca nut use warrants annual mucosal examination by a dentist or physician.
• Chronic liver disease or cirrhosis needs hepatocellular carcinoma surveillance.
• Any new cancer symptom like weight loss, persistent cough, blood in stool or urine, or abnormal bleeding.

Benefits of Cancer Screening

Key benefits are:

• Reduced treatment burden: Early cancers require less extensive surgery, shorter chemotherapy and less radiation.
• Prevention through polyp removal: Colonoscopy identifies and removes premalignant adenomas before they become cancers.
• Precancer identification: Cervical screening identifies CIN lesions that can be treated before invasive cancer develops.
• Peace of mind: A normal result provides reassurance and a defined plan for the next review.
• Better survival outcomes: Evidence across breast, colorectal, cervical and lung screening demonstrates reduced cancer-specific mortality in screened populations.

Conclusion

Cancer screening is the most effective population-level intervention for reducing cancer mortality, as it finds disease in people who feel well, at a stage when treatment is most likely to succeed. In India, where most cancers are diagnosed late, establishing a culture of regular, appropriate screening has the potential to improve outcomes meaningfully.

At Ramkrishna CARE Hospitals, Raipur cancer screening is an oncologist-led programme covering the full range of evidence-based screening tests from cervical cytology and mammography through colonoscopy and LDCT to whole-body PET CT on the uMI 550 for high-risk individuals and cancer survivors. Abnormal results are managed within the same integrated diagnostic and treatment infrastructure, without referral elsewhere.